Abstract
To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.
Original language | English |
---|---|
Pages (from-to) | 785-792 |
Number of pages | 8 |
Journal | Clinical & Translational Oncology |
Volume | 19 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2017 |
Keywords
- Rabies virus
- Cancer
- Spontaneous remission
- Immunotherapy
- NERVOUS-SYSTEM
- GLYCOPROTEIN
- CLEARANCE
- DELIVERY
- RECEPTOR
- THERAPY
- SIRNA
- RVG